Back
Finance

Pfizer Exceeds Q4 Earnings Estimates Amid Declining COVID Product Sales and Reaffirms 2026 Guidance

Generated on: Last updated: 1 sources
View source

Pfizer Exceeds Q4 Estimates, Reaffirms 2026 Guidance Amidst Strategic Shifts

Pfizer reported fourth-quarter results exceeding estimates, despite reduced demand for its COVID-19 related products. The company reaffirmed its 2026 guidance, signaling confidence in its long-term strategy and ongoing strategic pivots.

Pfizer reported fourth-quarter results exceeding estimates, despite reduced demand for its COVID-19 related products.

Q4 Financial Highlights

  • Adjusted Earnings per share: 66 cents, surpassing the 57 cents expected by analysts.
  • Revenue: $17.56 billion, exceeding the $16.95 billion expected. This represents a roughly 1% decrease from the prior year, primarily due to lower demand for its COVID-19 vaccine and Paxlovid.
  • Net Loss: $1.65 billion, or 29 cents per share, compared to a net income of $410 million, or 7 cents per share, in the same period last year.

Strategic Initiatives and Future Outlook

Pfizer is focusing on long-term investments to drive future growth. A key move includes the $10 billion acquisition of obesity biotech Metsera. The company also announced promising mid-stage data for a Metsera obesity injection, indicating it can be administered monthly and facilitates weight loss, highlighting a potential new revenue stream.

Alongside these growth initiatives, Pfizer is implementing significant cost reductions. The company is targeting approximately $7.7 billion in savings by the end of 2027 through two distinct initiatives, aiming to streamline operations and enhance financial efficiency.

2026 Guidance

For 2026, Pfizer anticipates adjusted profit between $2.80 and $3 per share, with revenue projected to be between $59.5 billion and $62.5 billion. This revenue forecast suggests sales will be largely flat compared to 2025.

Projected declines in 2026 sales are primarily attributed to an expected $1.5 billion year-over-year decrease in COVID-19 vaccine and Paxlovid sales, which are anticipated to reach $5 billion.

Additionally, the company expects another $1.5 billion reduction in sales due to certain products losing market exclusivity. This will lead to increased competition for key drugs like the pneumonia vaccine Prevnar, impacting overall sales figures.